

# Expression Pathology

**FOR IMMEDIATE RELEASE**

## **Expression Pathology Obtains Second U.S. Tissue Analysis Patent**

**Rockville, MD: March 24, 2011:** Expression Pathology Inc. announced today that the U.S. Patent and Trademark Office issued patent number 7,906,301, MULTIPLEX METHOD FOR INCREASED PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICAL SAMPLES, TISSUES AND CELLS. The claims of the patent cover methods that increase the range of proteins and protein modifications which can be analyzed using the company's patented methods used in the Liquid Tissue-SRM assays and the Liquid Tissue MS Protein Prep Kit.

Formalin fixation is the standard process used worldwide to preserve patient biopsies and surgical tissue, but it limits the ability to analyze proteins by advanced methodologies such as mass spectrometry. Liquid Tissue reagents and methods enable application of mass spectrometry for targeted quantitation of protein biomarkers.

"This new patent further strengthens our proprietary position with respect to methods for developing suitable target peptides for our Liquid Tissue-SRM assays", says Casey Eitner, the company's President and CEO. "Being able to digest the tissue with multiple enzymes, for example, opens the door to development of assays for target proteins and protein modifications that may not be amenable to analysis using standard SRM mass spectrometry methods".

### **About Expression Pathology**

Expression Pathology is a private biotech company advancing personalized medicine with assays that measure tumor signaling networks—at the functional protein level—in routine formalin-fixed paraffin-embedded (FFPE) patient tissue to individualize and improve cancer treatment decisions. The company is developing proprietary Liquid Tissue®-SRM companion diagnostic tests to support the development of drugs in clinical trials and to improve patient selection for targeted therapies already on the market. The company's rapidly expanding menu of assays includes many of the key protein pathways for which targeted therapies are being developed, including EGFR, IGF-1R, SPARC, SRC, truncated (p95) HER2, HER3, and cMET.

The Liquid Tissue®-SRM assays make possible multiplexed protein quantification and Expression Pathology is exploiting its ability to accurately measure cancer pathway proteins and their activation, or phosphorylation states, and to do so in standard patient tissue and core needle biopsies, to develop more informative assays that can be widely adopted in medical practice.

For more information, please contact

Peter Tunon, VP Sales and Marketing  
Expression Pathology Inc.  
9620 Medical Center Drive  
Rockville, MD 20850

Phone: 301.977.3654

Email: [p.tunon@expressionpathology.com](mailto:p.tunon@expressionpathology.com)

**Expression Pathology Inc.**

9620 Medical Center Drive • Suite 100 • Rockville, Maryland 20850

phone 301.977.3654 • fax 301.926.9283 • [www.expressionpathology.com](http://www.expressionpathology.com)